nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—KIT—muscle cancer	0.452	1	CbGaD
Ponatinib—ABCB11—Vincristine—muscle cancer	0.0491	0.172	CbGbCtD
Ponatinib—ABCG2—Dactinomycin—muscle cancer	0.0379	0.133	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—muscle cancer	0.0307	0.108	CbGbCtD
Ponatinib—ABCG2—Vincristine—muscle cancer	0.0233	0.0818	CbGbCtD
Ponatinib—ABCG2—Etoposide—muscle cancer	0.0214	0.075	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—muscle cancer	0.0146	0.0511	CbGbCtD
Ponatinib—ABCG2—Methotrexate—muscle cancer	0.0141	0.0495	CbGbCtD
Ponatinib—ABCB1—Dactinomycin—muscle cancer	0.0137	0.0479	CbGbCtD
Ponatinib—CYP3A5—Vincristine—muscle cancer	0.0129	0.0453	CbGbCtD
Ponatinib—CYP3A5—Etoposide—muscle cancer	0.0119	0.0415	CbGbCtD
Ponatinib—CYP2C8—Etoposide—muscle cancer	0.0114	0.0399	CbGbCtD
Ponatinib—ABCB1—Vincristine—muscle cancer	0.00842	0.0295	CbGbCtD
Ponatinib—ABCB1—Etoposide—muscle cancer	0.00771	0.027	CbGbCtD
Ponatinib—ABCB1—Doxorubicin—muscle cancer	0.00526	0.0184	CbGbCtD
Ponatinib—ABCB1—Methotrexate—muscle cancer	0.0051	0.0179	CbGbCtD
Ponatinib—CYP3A4—Vincristine—muscle cancer	0.00504	0.0177	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—muscle cancer	0.00496	0.0174	CbGbCtD
Ponatinib—CYP3A4—Etoposide—muscle cancer	0.00462	0.0162	CbGbCtD
Ponatinib—FGFR3—appendage—muscle cancer	0.00429	0.0691	CbGeAlD
Ponatinib—CYP3A4—Doxorubicin—muscle cancer	0.00315	0.011	CbGbCtD
Ponatinib—KDR—hindlimb—muscle cancer	0.00256	0.0413	CbGeAlD
Ponatinib—KDR—appendage—muscle cancer	0.0022	0.0354	CbGeAlD
Ponatinib—FGFR4—embryo—muscle cancer	0.00209	0.0336	CbGeAlD
Ponatinib—Nilotinib—KIT—muscle cancer	0.00193	0.545	CrCbGaD
Ponatinib—FGFR4—Podofilox—Etoposide—muscle cancer	0.00168	0.492	CbGdCrCtD
Ponatinib—Imatinib—KIT—muscle cancer	0.00161	0.455	CrCbGaD
Ponatinib—FGFR4—renal system—muscle cancer	0.00158	0.0255	CbGeAlD
Ponatinib—FGFR3—embryo—muscle cancer	0.00142	0.0229	CbGeAlD
Ponatinib—FGFR4—Vinblastine—Vincristine—muscle cancer	0.00115	0.338	CbGdCrCtD
Ponatinib—FGFR3—renal system—muscle cancer	0.00108	0.0174	CbGeAlD
Ponatinib—FGFR4—head—muscle cancer	0.00106	0.017	CbGeAlD
Ponatinib—FGFR4—testis—muscle cancer	0.00102	0.0164	CbGeAlD
Ponatinib—RET—embryo—muscle cancer	0.000981	0.0158	CbGeAlD
Ponatinib—BCR—renal system—muscle cancer	0.000932	0.015	CbGeAlD
Ponatinib—FGFR2—embryo—muscle cancer	0.000932	0.015	CbGeAlD
Ponatinib—TEK—embryo—muscle cancer	0.000894	0.0144	CbGeAlD
Ponatinib—BCR—cardiac atrium—muscle cancer	0.000835	0.0135	CbGeAlD
Ponatinib—PDGFRA—embryo—muscle cancer	0.000809	0.013	CbGeAlD
Ponatinib—SRC—embryo—muscle cancer	0.000794	0.0128	CbGeAlD
Ponatinib—FGFR1—cardiac atrium—muscle cancer	0.000743	0.012	CbGeAlD
Ponatinib—RET—renal system—muscle cancer	0.000742	0.012	CbGeAlD
Ponatinib—FGFR2—smooth muscle tissue—muscle cancer	0.000733	0.0118	CbGeAlD
Ponatinib—KDR—embryo—muscle cancer	0.00073	0.0118	CbGeAlD
Ponatinib—BCR—tendon—muscle cancer	0.000728	0.0117	CbGeAlD
Ponatinib—LYN—head—muscle cancer	0.000725	0.0117	CbGeAlD
Ponatinib—FGFR3—head—muscle cancer	0.000721	0.0116	CbGeAlD
Ponatinib—FGFR2—renal system—muscle cancer	0.000705	0.0114	CbGeAlD
Ponatinib—BCR—bone marrow—muscle cancer	0.000705	0.0114	CbGeAlD
Ponatinib—TEK—smooth muscle tissue—muscle cancer	0.000703	0.0113	CbGeAlD
Ponatinib—FLT3—bone marrow—muscle cancer	0.0007	0.0113	CbGeAlD
Ponatinib—FGFR3—testis—muscle cancer	0.000697	0.0112	CbGeAlD
Ponatinib—TEK—renal system—muscle cancer	0.000676	0.0109	CbGeAlD
Ponatinib—BCR—vagina—muscle cancer	0.000675	0.0109	CbGeAlD
Ponatinib—FGFR1—tendon—muscle cancer	0.000648	0.0104	CbGeAlD
Ponatinib—KIT—embryo—muscle cancer	0.000647	0.0104	CbGeAlD
Ponatinib—PDGFRA—smooth muscle tissue—muscle cancer	0.000636	0.0103	CbGeAlD
Ponatinib—SRC—smooth muscle tissue—muscle cancer	0.000624	0.0101	CbGeAlD
Ponatinib—BCR—head—muscle cancer	0.000624	0.0101	CbGeAlD
Ponatinib—PDGFRA—renal system—muscle cancer	0.000613	0.00987	CbGeAlD
Ponatinib—TEK—cardiac atrium—muscle cancer	0.000606	0.00976	CbGeAlD
Ponatinib—BCR—testis—muscle cancer	0.000603	0.00971	CbGeAlD
Ponatinib—FGFR1—vagina—muscle cancer	0.000601	0.00968	CbGeAlD
Ponatinib—SRC—renal system—muscle cancer	0.000601	0.00968	CbGeAlD
Ponatinib—FLT3—testis—muscle cancer	0.000598	0.00964	CbGeAlD
Ponatinib—RET—tendon—muscle cancer	0.00058	0.00934	CbGeAlD
Ponatinib—KDR—smooth muscle tissue—muscle cancer	0.000574	0.00925	CbGeAlD
Ponatinib—ABL1—embryo—muscle cancer	0.000563	0.00908	CbGeAlD
Ponatinib—LCK—bone marrow—muscle cancer	0.000561	0.00905	CbGeAlD
Ponatinib—KDR—renal system—muscle cancer	0.000553	0.00891	CbGeAlD
Ponatinib—SRC—cardiac atrium—muscle cancer	0.000538	0.00867	CbGeAlD
Ponatinib—LCK—vagina—muscle cancer	0.000538	0.00867	CbGeAlD
Ponatinib—FGFR1—testis—muscle cancer	0.000536	0.00864	CbGeAlD
Ponatinib—TEK—tendon—muscle cancer	0.000528	0.00851	CbGeAlD
Ponatinib—KIT—smooth muscle tissue—muscle cancer	0.000509	0.0082	CbGeAlD
Ponatinib—RET—head—muscle cancer	0.000497	0.008	CbGeAlD
Ponatinib—KDR—cardiac atrium—muscle cancer	0.000495	0.00798	CbGeAlD
Ponatinib—KIT—renal system—muscle cancer	0.00049	0.00789	CbGeAlD
Ponatinib—RET—testis—muscle cancer	0.00048	0.00773	CbGeAlD
Ponatinib—LCK—testis—muscle cancer	0.00048	0.00773	CbGeAlD
Ponatinib—PDGFRA—tendon—muscle cancer	0.000478	0.00771	CbGeAlD
Ponatinib—FGFR2—head—muscle cancer	0.000472	0.00761	CbGeAlD
Ponatinib—ABCB11—testis—muscle cancer	0.000469	0.00755	CbGeAlD
Ponatinib—FGFR2—testis—muscle cancer	0.000456	0.00735	CbGeAlD
Ponatinib—TEK—head—muscle cancer	0.000452	0.00729	CbGeAlD
Ponatinib—PDGFRA—vagina—muscle cancer	0.000444	0.00715	CbGeAlD
Ponatinib—ABL1—smooth muscle tissue—muscle cancer	0.000443	0.00714	CbGeAlD
Ponatinib—TEK—testis—muscle cancer	0.000437	0.00704	CbGeAlD
Ponatinib—KDR—tendon—muscle cancer	0.000431	0.00695	CbGeAlD
Ponatinib—ABL1—renal system—muscle cancer	0.000426	0.00687	CbGeAlD
Ponatinib—KDR—bone marrow—muscle cancer	0.000418	0.00673	CbGeAlD
Ponatinib—PDGFRA—head—muscle cancer	0.00041	0.00661	CbGeAlD
Ponatinib—SRC—head—muscle cancer	0.000402	0.00648	CbGeAlD
Ponatinib—KDR—vagina—muscle cancer	0.0004	0.00645	CbGeAlD
Ponatinib—PDGFRA—testis—muscle cancer	0.000396	0.00638	CbGeAlD
Ponatinib—SRC—testis—muscle cancer	0.000388	0.00626	CbGeAlD
Ponatinib—ABL1—cardiac atrium—muscle cancer	0.000382	0.00615	CbGeAlD
Ponatinib—KIT—bone marrow—muscle cancer	0.00037	0.00597	CbGeAlD
Ponatinib—KDR—head—muscle cancer	0.00037	0.00596	CbGeAlD
Ponatinib—KDR—testis—muscle cancer	0.000357	0.00576	CbGeAlD
Ponatinib—KIT—vagina—muscle cancer	0.000355	0.00572	CbGeAlD
Ponatinib—ABL1—tendon—muscle cancer	0.000333	0.00536	CbGeAlD
Ponatinib—KIT—head—muscle cancer	0.000328	0.00528	CbGeAlD
Ponatinib—ABL1—bone marrow—muscle cancer	0.000322	0.0052	CbGeAlD
Ponatinib—KIT—testis—muscle cancer	0.000317	0.0051	CbGeAlD
Ponatinib—ABL1—vagina—muscle cancer	0.000309	0.00498	CbGeAlD
Ponatinib—ABL1—head—muscle cancer	0.000285	0.0046	CbGeAlD
Ponatinib—CYP2C8—renal system—muscle cancer	0.000277	0.00446	CbGeAlD
Ponatinib—ABL1—testis—muscle cancer	0.000276	0.00444	CbGeAlD
Ponatinib—CYP3A5—renal system—muscle cancer	0.00025	0.00402	CbGeAlD
Ponatinib—ABCG2—bone marrow—muscle cancer	0.000203	0.00328	CbGeAlD
Ponatinib—CYP2C8—vagina—muscle cancer	0.0002	0.00323	CbGeAlD
Ponatinib—ABCG2—vagina—muscle cancer	0.000195	0.00314	CbGeAlD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—muscle cancer	0.000193	0.0566	CbGdCrCtD
Ponatinib—ABL1—Epirubicin—Doxorubicin—muscle cancer	0.000193	0.0566	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Doxorubicin—muscle cancer	0.000193	0.0566	CbGdCrCtD
Ponatinib—CYP3A4—renal system—muscle cancer	0.000187	0.00302	CbGeAlD
Ponatinib—Musculoskeletal pain—Doxorubicin—muscle cancer	0.000187	0.00243	CcSEcCtD
Ponatinib—Back pain—Vincristine—muscle cancer	0.000186	0.00241	CcSEcCtD
Ponatinib—Sepsis—Methotrexate—muscle cancer	0.000185	0.0024	CcSEcCtD
Ponatinib—Pulmonary embolism—Doxorubicin—muscle cancer	0.000185	0.0024	CcSEcCtD
Ponatinib—Phosphatase alkaline increased—Doxorubicin—muscle cancer	0.000185	0.0024	CcSEcCtD
Ponatinib—CYP2D6—renal system—muscle cancer	0.000184	0.00297	CbGeAlD
Ponatinib—Myalgia—Dactinomycin—muscle cancer	0.000183	0.00238	CcSEcCtD
Ponatinib—CYP3A5—vagina—muscle cancer	0.000181	0.00291	CbGeAlD
Ponatinib—Influenza like illness—Doxorubicin—muscle cancer	0.00018	0.00233	CcSEcCtD
Ponatinib—CYP2C8—testis—muscle cancer	0.000179	0.00288	CbGeAlD
Ponatinib—Hypoaesthesia—Etoposide—muscle cancer	0.000178	0.00231	CcSEcCtD
Ponatinib—Anaemia—Vincristine—muscle cancer	0.000178	0.00231	CcSEcCtD
Ponatinib—Skin exfoliation—Doxorubicin—muscle cancer	0.000177	0.00229	CcSEcCtD
Ponatinib—Oedema—Dactinomycin—muscle cancer	0.000176	0.00228	CcSEcCtD
Ponatinib—Fluid retention—Doxorubicin—muscle cancer	0.000176	0.00228	CcSEcCtD
Ponatinib—ABCB1—embryo—muscle cancer	0.000175	0.00282	CbGeAlD
Ponatinib—Infection—Dactinomycin—muscle cancer	0.000175	0.00226	CcSEcCtD
Ponatinib—ABCG2—testis—muscle cancer	0.000174	0.0028	CbGeAlD
Ponatinib—Neuropathy—Doxorubicin—muscle cancer	0.000174	0.00225	CcSEcCtD
Ponatinib—Leukopenia—Vincristine—muscle cancer	0.000172	0.00223	CcSEcCtD
Ponatinib—Thrombocytopenia—Dactinomycin—muscle cancer	0.000172	0.00223	CcSEcCtD
Ponatinib—Dry eye—Doxorubicin—muscle cancer	0.000171	0.00221	CcSEcCtD
Ponatinib—Eye disorder—Etoposide—muscle cancer	0.000167	0.00217	CcSEcCtD
Ponatinib—Ecchymosis—Doxorubicin—muscle cancer	0.000167	0.00217	CcSEcCtD
Ponatinib—Flushing—Etoposide—muscle cancer	0.000166	0.00215	CcSEcCtD
Ponatinib—Cardiac disorder—Etoposide—muscle cancer	0.000166	0.00215	CcSEcCtD
Ponatinib—Hypertension—Vincristine—muscle cancer	0.000166	0.00215	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Methotrexate—muscle cancer	0.000164	0.00213	CcSEcCtD
Ponatinib—Myalgia—Vincristine—muscle cancer	0.000164	0.00212	CcSEcCtD
Ponatinib—Angiopathy—Etoposide—muscle cancer	0.000163	0.00211	CcSEcCtD
Ponatinib—Mediastinal disorder—Etoposide—muscle cancer	0.000161	0.00209	CcSEcCtD
Ponatinib—Chills—Etoposide—muscle cancer	0.000161	0.00208	CcSEcCtD
Ponatinib—Sepsis—Doxorubicin—muscle cancer	0.000161	0.00208	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00016	0.00208	CcSEcCtD
Ponatinib—Alopecia—Etoposide—muscle cancer	0.000158	0.00205	CcSEcCtD
Ponatinib—Cerebrovascular accident—Methotrexate—muscle cancer	0.000158	0.00205	CcSEcCtD
Ponatinib—Lethargy—Methotrexate—muscle cancer	0.000158	0.00205	CcSEcCtD
Ponatinib—Oedema—Vincristine—muscle cancer	0.000157	0.00204	CcSEcCtD
Ponatinib—Infection—Vincristine—muscle cancer	0.000156	0.00202	CcSEcCtD
Ponatinib—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.000154	0.002	CcSEcCtD
Ponatinib—Nervous system disorder—Vincristine—muscle cancer	0.000154	0.002	CcSEcCtD
Ponatinib—Thrombocytopenia—Vincristine—muscle cancer	0.000154	0.00199	CcSEcCtD
Ponatinib—Decreased appetite—Dactinomycin—muscle cancer	0.000153	0.00198	CcSEcCtD
Ponatinib—Hyperhidrosis—Vincristine—muscle cancer	0.000152	0.00197	CcSEcCtD
Ponatinib—Fatigue—Dactinomycin—muscle cancer	0.000152	0.00196	CcSEcCtD
Ponatinib—Back pain—Etoposide—muscle cancer	0.000151	0.00195	CcSEcCtD
Ponatinib—Pain—Dactinomycin—muscle cancer	0.00015	0.00195	CcSEcCtD
Ponatinib—Muscle spasms—Etoposide—muscle cancer	0.00015	0.00194	CcSEcCtD
Ponatinib—Cardiac failure congestive—Doxorubicin—muscle cancer	0.000148	0.00192	CcSEcCtD
Ponatinib—Anaemia—Etoposide—muscle cancer	0.000144	0.00187	CcSEcCtD
Ponatinib—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000144	0.00186	CcSEcCtD
Ponatinib—Hot flush—Doxorubicin—muscle cancer	0.000144	0.00186	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000143	0.00185	CcSEcCtD
Ponatinib—Menopausal symptoms—Doxorubicin—muscle cancer	0.000142	0.00184	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Doxorubicin—muscle cancer	0.000142	0.00184	CcSEcCtD
Ponatinib—Insomnia—Vincristine—muscle cancer	0.000142	0.00184	CcSEcCtD
Ponatinib—Paraesthesia—Vincristine—muscle cancer	0.000141	0.00183	CcSEcCtD
Ponatinib—Breast disorder—Methotrexate—muscle cancer	0.00014	0.00182	CcSEcCtD
Ponatinib—Leukopenia—Etoposide—muscle cancer	0.00014	0.00181	CcSEcCtD
Ponatinib—Body temperature increased—Dactinomycin—muscle cancer	0.000139	0.0018	CcSEcCtD
Ponatinib—Abdominal pain—Dactinomycin—muscle cancer	0.000139	0.0018	CcSEcCtD
Ponatinib—Cardiac failure—Doxorubicin—muscle cancer	0.000138	0.00178	CcSEcCtD
Ponatinib—Cerebrovascular accident—Doxorubicin—muscle cancer	0.000137	0.00178	CcSEcCtD
Ponatinib—Lethargy—Doxorubicin—muscle cancer	0.000137	0.00178	CcSEcCtD
Ponatinib—Decreased appetite—Vincristine—muscle cancer	0.000137	0.00177	CcSEcCtD
Ponatinib—Cough—Etoposide—muscle cancer	0.000136	0.00176	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000136	0.00176	CcSEcCtD
Ponatinib—Fatigue—Vincristine—muscle cancer	0.000135	0.00176	CcSEcCtD
Ponatinib—Hyponatraemia—Doxorubicin—muscle cancer	0.000135	0.00175	CcSEcCtD
Ponatinib—Hypertension—Etoposide—muscle cancer	0.000135	0.00174	CcSEcCtD
Ponatinib—Pain—Vincristine—muscle cancer	0.000134	0.00174	CcSEcCtD
Ponatinib—Constipation—Vincristine—muscle cancer	0.000134	0.00174	CcSEcCtD
Ponatinib—Pain in extremity—Doxorubicin—muscle cancer	0.000134	0.00174	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000134	0.00174	CcSEcCtD
Ponatinib—ABCB1—renal system—muscle cancer	0.000133	0.00214	CbGeAlD
Ponatinib—Migraine—Doxorubicin—muscle cancer	0.000132	0.00171	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000132	0.00171	CcSEcCtD
Ponatinib—Pancreatitis—Methotrexate—muscle cancer	0.000131	0.0017	CcSEcCtD
Ponatinib—Face oedema—Doxorubicin—muscle cancer	0.00013	0.00168	CcSEcCtD
Ponatinib—Abdominal discomfort—Methotrexate—muscle cancer	0.000128	0.00167	CcSEcCtD
Ponatinib—Gastrointestinal pain—Vincristine—muscle cancer	0.000128	0.00166	CcSEcCtD
Ponatinib—Pancytopenia—Methotrexate—muscle cancer	0.000127	0.00165	CcSEcCtD
Ponatinib—Infection—Etoposide—muscle cancer	0.000126	0.00164	CcSEcCtD
Ponatinib—Asthenia—Dactinomycin—muscle cancer	0.000126	0.00163	CcSEcCtD
Ponatinib—Blood creatinine increased—Doxorubicin—muscle cancer	0.000126	0.00163	CcSEcCtD
Ponatinib—Neutropenia—Methotrexate—muscle cancer	0.000125	0.00162	CcSEcCtD
Ponatinib—Dehydration—Doxorubicin—muscle cancer	0.000125	0.00162	CcSEcCtD
Ponatinib—Thrombocytopenia—Etoposide—muscle cancer	0.000125	0.00161	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000125	0.00161	CcSEcCtD
Ponatinib—Abdominal pain—Vincristine—muscle cancer	0.000124	0.00161	CcSEcCtD
Ponatinib—Body temperature increased—Vincristine—muscle cancer	0.000124	0.00161	CcSEcCtD
Ponatinib—Skin disorder—Etoposide—muscle cancer	0.000124	0.0016	CcSEcCtD
Ponatinib—Erectile dysfunction—Methotrexate—muscle cancer	0.000123	0.0016	CcSEcCtD
Ponatinib—CYP2D6—head—muscle cancer	0.000123	0.00199	CbGeAlD
Ponatinib—Dry skin—Doxorubicin—muscle cancer	0.000123	0.0016	CcSEcCtD
Ponatinib—Hyperhidrosis—Etoposide—muscle cancer	0.000123	0.00159	CcSEcCtD
Ponatinib—Hypokalaemia—Doxorubicin—muscle cancer	0.000122	0.00158	CcSEcCtD
Ponatinib—Breast disorder—Doxorubicin—muscle cancer	0.000121	0.00157	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000121	0.00157	CcSEcCtD
Ponatinib—Diarrhoea—Dactinomycin—muscle cancer	0.00012	0.00156	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—muscle cancer	0.00012	0.00156	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—muscle cancer	0.00012	0.00156	CcSEcCtD
Ponatinib—Infestation—Methotrexate—muscle cancer	0.00012	0.00155	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—muscle cancer	0.00012	0.00155	CcSEcCtD
Ponatinib—CYP2D6—testis—muscle cancer	0.000119	0.00192	CbGeAlD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000118	0.00153	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—muscle cancer	0.000117	0.00151	CcSEcCtD
Ponatinib—Stomatitis—Methotrexate—muscle cancer	0.000116	0.00151	CcSEcCtD
Ponatinib—Paraesthesia—Etoposide—muscle cancer	0.000114	0.00148	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—muscle cancer	0.000114	0.00147	CcSEcCtD
Ponatinib—Dyspnoea—Etoposide—muscle cancer	0.000113	0.00147	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—muscle cancer	0.000113	0.00147	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—muscle cancer	0.000113	0.00146	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—muscle cancer	0.000113	0.00146	CcSEcCtD
Ponatinib—Asthenia—Vincristine—muscle cancer	0.000113	0.00146	CcSEcCtD
Ponatinib—Vomiting—Dactinomycin—muscle cancer	0.000112	0.00145	CcSEcCtD
Ponatinib—Rash—Dactinomycin—muscle cancer	0.000111	0.00144	CcSEcCtD
Ponatinib—Decreased appetite—Etoposide—muscle cancer	0.000111	0.00143	CcSEcCtD
Ponatinib—Pancytopenia—Doxorubicin—muscle cancer	0.00011	0.00143	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Etoposide—muscle cancer	0.00011	0.00142	CcSEcCtD
Ponatinib—Fatigue—Etoposide—muscle cancer	0.00011	0.00142	CcSEcCtD
Ponatinib—Constipation—Etoposide—muscle cancer	0.000109	0.00141	CcSEcCtD
Ponatinib—Pain—Etoposide—muscle cancer	0.000109	0.00141	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—muscle cancer	0.000109	0.00141	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000108	0.0014	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—muscle cancer	0.000108	0.0014	CcSEcCtD
Ponatinib—Diarrhoea—Vincristine—muscle cancer	0.000107	0.00139	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—muscle cancer	0.000107	0.00139	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—muscle cancer	0.000105	0.00136	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—muscle cancer	0.000105	0.00136	CcSEcCtD
Ponatinib—Nausea—Dactinomycin—muscle cancer	0.000104	0.00135	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—muscle cancer	0.000104	0.00135	CcSEcCtD
Ponatinib—Gastrointestinal pain—Etoposide—muscle cancer	0.000104	0.00135	CcSEcCtD
Ponatinib—Dizziness—Vincristine—muscle cancer	0.000104	0.00135	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—muscle cancer	0.000103	0.00134	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—muscle cancer	0.000103	0.00134	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—muscle cancer	0.000103	0.00134	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000101	0.00131	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—muscle cancer	0.000101	0.00131	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—muscle cancer	0.000101	0.00131	CcSEcCtD
Ponatinib—Body temperature increased—Etoposide—muscle cancer	0.000101	0.0013	CcSEcCtD
Ponatinib—Abdominal pain—Etoposide—muscle cancer	0.000101	0.0013	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—muscle cancer	0.000101	0.0013	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—muscle cancer	0.0001	0.0013	CcSEcCtD
Ponatinib—ABCB1—bone marrow—muscle cancer	0.0001	0.00162	CbGeAlD
Ponatinib—Vomiting—Vincristine—muscle cancer	9.99e-05	0.00129	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—muscle cancer	9.96e-05	0.00129	CcSEcCtD
Ponatinib—Rash—Vincristine—muscle cancer	9.9e-05	0.00128	CcSEcCtD
Ponatinib—Dermatitis—Vincristine—muscle cancer	9.9e-05	0.00128	CcSEcCtD
Ponatinib—Headache—Vincristine—muscle cancer	9.84e-05	0.00128	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—muscle cancer	9.79e-05	0.00127	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—muscle cancer	9.76e-05	0.00126	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—muscle cancer	9.73e-05	0.00126	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—muscle cancer	9.67e-05	0.00125	CcSEcCtD
Ponatinib—Chills—Methotrexate—muscle cancer	9.63e-05	0.00125	CcSEcCtD
Ponatinib—ABCB1—vagina—muscle cancer	9.6e-05	0.00155	CbGeAlD
Ponatinib—Alopecia—Methotrexate—muscle cancer	9.48e-05	0.00123	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—muscle cancer	9.4e-05	0.00122	CcSEcCtD
Ponatinib—Erythema—Methotrexate—muscle cancer	9.34e-05	0.00121	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—muscle cancer	9.34e-05	0.00121	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—muscle cancer	9.34e-05	0.00121	CcSEcCtD
Ponatinib—Nausea—Vincristine—muscle cancer	9.33e-05	0.00121	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—muscle cancer	9.29e-05	0.0012	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—muscle cancer	9.24e-05	0.0012	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—muscle cancer	9.15e-05	0.00119	CcSEcCtD
Ponatinib—Asthenia—Etoposide—muscle cancer	9.13e-05	0.00118	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—muscle cancer	9.13e-05	0.00118	CcSEcCtD
Ponatinib—Back pain—Methotrexate—muscle cancer	9.03e-05	0.00117	CcSEcCtD
Ponatinib—Pruritus—Etoposide—muscle cancer	9e-05	0.00117	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—muscle cancer	8.95e-05	0.00116	CcSEcCtD
Ponatinib—ABCB1—head—muscle cancer	8.87e-05	0.00143	CbGeAlD
Ponatinib—Vision blurred—Methotrexate—muscle cancer	8.8e-05	0.00114	CcSEcCtD
Ponatinib—Diarrhoea—Etoposide—muscle cancer	8.71e-05	0.00113	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—muscle cancer	8.68e-05	0.00113	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—muscle cancer	8.63e-05	0.00112	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—muscle cancer	8.62e-05	0.00112	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—muscle cancer	8.62e-05	0.00112	CcSEcCtD
Ponatinib—ABCB1—testis—muscle cancer	8.57e-05	0.00138	CbGeAlD
Ponatinib—Angiopathy—Doxorubicin—muscle cancer	8.43e-05	0.00109	CcSEcCtD
Ponatinib—Dizziness—Etoposide—muscle cancer	8.42e-05	0.00109	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—muscle cancer	8.37e-05	0.00109	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—muscle cancer	8.36e-05	0.00108	CcSEcCtD
Ponatinib—Chills—Doxorubicin—muscle cancer	8.34e-05	0.00108	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—muscle cancer	8.3e-05	0.00108	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—muscle cancer	8.21e-05	0.00106	CcSEcCtD
Ponatinib—Cough—Methotrexate—muscle cancer	8.15e-05	0.00106	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—muscle cancer	8.14e-05	0.00105	CcSEcCtD
Ponatinib—Vomiting—Etoposide—muscle cancer	8.09e-05	0.00105	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—muscle cancer	8.09e-05	0.00105	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—muscle cancer	8.09e-05	0.00105	CcSEcCtD
Ponatinib—Rash—Etoposide—muscle cancer	8.02e-05	0.00104	CcSEcCtD
Ponatinib—Dermatitis—Etoposide—muscle cancer	8.02e-05	0.00104	CcSEcCtD
Ponatinib—Headache—Etoposide—muscle cancer	7.97e-05	0.00103	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—muscle cancer	7.95e-05	0.00103	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—muscle cancer	7.95e-05	0.00103	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	7.9e-05	0.00102	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—muscle cancer	7.82e-05	0.00101	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—muscle cancer	7.78e-05	0.00101	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—muscle cancer	7.62e-05	0.000988	CcSEcCtD
Ponatinib—Infection—Methotrexate—muscle cancer	7.57e-05	0.000981	CcSEcCtD
Ponatinib—Nausea—Etoposide—muscle cancer	7.56e-05	0.00098	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—muscle cancer	7.48e-05	0.000969	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—muscle cancer	7.47e-05	0.000969	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—muscle cancer	7.46e-05	0.000967	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—muscle cancer	7.4e-05	0.00096	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—muscle cancer	7.37e-05	0.000955	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—muscle cancer	7.24e-05	0.000938	CcSEcCtD
Ponatinib—Cough—Doxorubicin—muscle cancer	7.06e-05	0.000915	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—muscle cancer	6.98e-05	0.000905	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methotrexate—muscle cancer	6.94e-05	0.0009	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—muscle cancer	6.89e-05	0.000893	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—muscle cancer	6.89e-05	0.000892	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—muscle cancer	6.89e-05	0.000892	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—muscle cancer	6.84e-05	0.000887	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	6.84e-05	0.000886	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—muscle cancer	6.8e-05	0.000881	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—muscle cancer	6.73e-05	0.000873	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—muscle cancer	6.71e-05	0.00087	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—muscle cancer	6.63e-05	0.000859	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—muscle cancer	6.6e-05	0.000855	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—muscle cancer	6.58e-05	0.000853	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—muscle cancer	6.57e-05	0.000852	CcSEcCtD
Ponatinib—Infection—Doxorubicin—muscle cancer	6.56e-05	0.00085	CcSEcCtD
Ponatinib—Pain—Methotrexate—muscle cancer	6.52e-05	0.000845	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—muscle cancer	6.47e-05	0.000839	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—muscle cancer	6.46e-05	0.000837	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—muscle cancer	6.41e-05	0.000831	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—muscle cancer	6.38e-05	0.000827	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—muscle cancer	6.23e-05	0.000808	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—muscle cancer	6.03e-05	0.000781	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—muscle cancer	6.03e-05	0.000781	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	6.01e-05	0.000779	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—muscle cancer	5.97e-05	0.000774	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—muscle cancer	5.93e-05	0.000768	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—muscle cancer	5.88e-05	0.000763	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—muscle cancer	5.81e-05	0.000753	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—muscle cancer	5.74e-05	0.000744	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	5.7e-05	0.000738	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—muscle cancer	5.69e-05	0.000737	CcSEcCtD
Ponatinib—Pain—Doxorubicin—muscle cancer	5.64e-05	0.000731	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—muscle cancer	5.64e-05	0.000731	CcSEcCtD
Ponatinib—Asthenia—Methotrexate—muscle cancer	5.47e-05	0.000709	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—muscle cancer	5.4e-05	0.000699	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—muscle cancer	5.39e-05	0.000699	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—muscle cancer	5.22e-05	0.000676	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—muscle cancer	5.22e-05	0.000676	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—muscle cancer	5.22e-05	0.000676	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—muscle cancer	5.04e-05	0.000653	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—muscle cancer	4.85e-05	0.000628	CcSEcCtD
Ponatinib—Rash—Methotrexate—muscle cancer	4.81e-05	0.000623	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—muscle cancer	4.8e-05	0.000622	CcSEcCtD
Ponatinib—Headache—Methotrexate—muscle cancer	4.78e-05	0.000619	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—muscle cancer	4.74e-05	0.000614	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—muscle cancer	4.67e-05	0.000605	CcSEcCtD
Ponatinib—Nausea—Methotrexate—muscle cancer	4.53e-05	0.000587	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—muscle cancer	4.52e-05	0.000585	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—muscle cancer	4.36e-05	0.000566	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—muscle cancer	4.2e-05	0.000544	CcSEcCtD
Ponatinib—Rash—Doxorubicin—muscle cancer	4.16e-05	0.000539	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—muscle cancer	4.16e-05	0.000539	CcSEcCtD
Ponatinib—Headache—Doxorubicin—muscle cancer	4.13e-05	0.000536	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—muscle cancer	3.92e-05	0.000508	CcSEcCtD
Ponatinib—PDGFRA—Disease—HMGA1—muscle cancer	2.13e-05	0.000182	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PTCH1—muscle cancer	2.12e-05	0.000181	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.1e-05	0.00018	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—FOXO4—muscle cancer	2.09e-05	0.000179	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—FOXO1—muscle cancer	2.09e-05	0.000179	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—ENO2—muscle cancer	2.08e-05	0.000178	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—FOXO4—muscle cancer	2.07e-05	0.000177	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—FOXO4—muscle cancer	2.07e-05	0.000177	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—KIT—muscle cancer	2.06e-05	0.000176	CbGpPWpGaD
Ponatinib—FGFR2—Disease—FOXO4—muscle cancer	2.05e-05	0.000176	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CNR1—muscle cancer	2.05e-05	0.000175	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—IGF2—muscle cancer	2.02e-05	0.000173	CbGpPWpGaD
Ponatinib—KIT—Disease—FOXO4—muscle cancer	2.02e-05	0.000172	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—KIT—muscle cancer	2e-05	0.000171	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—KIT—muscle cancer	2e-05	0.000171	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—MDM2—muscle cancer	1.99e-05	0.000171	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD34—muscle cancer	1.95e-05	0.000166	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—MDM2—muscle cancer	1.94e-05	0.000166	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—KIT—muscle cancer	1.92e-05	0.000164	CbGpPWpGaD
Ponatinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.92e-05	0.000164	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—KIT—muscle cancer	1.92e-05	0.000164	CbGpPWpGaD
Ponatinib—FGFR1—Disease—FOXO4—muscle cancer	1.91e-05	0.000164	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—FH—muscle cancer	1.91e-05	0.000163	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—FOXO4—muscle cancer	1.91e-05	0.000163	CbGpPWpGaD
Ponatinib—FGFR1—Axon guidance—VEGFA—muscle cancer	1.9e-05	0.000163	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—FOXO1—muscle cancer	1.9e-05	0.000162	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—FOXO1—muscle cancer	1.9e-05	0.000162	CbGpPWpGaD
Ponatinib—SRC—TGF-beta Signaling Pathway—TP53—muscle cancer	1.88e-05	0.000161	CbGpPWpGaD
Ponatinib—LCK—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	1.86e-05	0.000159	CbGpPWpGaD
Ponatinib—SRC—Focal Adhesion—VEGFA—muscle cancer	1.86e-05	0.000159	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.85e-05	0.000158	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—VEGFA—muscle cancer	1.84e-05	0.000158	CbGpPWpGaD
Ponatinib—LYN—Immune System—FOXO4—muscle cancer	1.82e-05	0.000156	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—FOXO4—muscle cancer	1.82e-05	0.000156	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—FOXO1—muscle cancer	1.82e-05	0.000156	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—KIT—muscle cancer	1.82e-05	0.000156	CbGpPWpGaD
Ponatinib—ABL1—Immune System—FOXO4—muscle cancer	1.81e-05	0.000155	CbGpPWpGaD
Ponatinib—FGFR4—Disease—MDM2—muscle cancer	1.79e-05	0.000153	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CNR1—muscle cancer	1.79e-05	0.000153	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—MDM2—muscle cancer	1.78e-05	0.000152	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—MDM2—muscle cancer	1.77e-05	0.000151	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—KIT—muscle cancer	1.76e-05	0.000151	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—KIT—muscle cancer	1.75e-05	0.00015	CbGpPWpGaD
Ponatinib—FGFR4—Disease—PTGS2—muscle cancer	1.72e-05	0.000147	CbGpPWpGaD
Ponatinib—LCK—Disease—ENO2—muscle cancer	1.69e-05	0.000145	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—MDM2—muscle cancer	1.69e-05	0.000145	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—KIT—muscle cancer	1.69e-05	0.000145	CbGpPWpGaD
Ponatinib—FGFR3—Disease—KIT—muscle cancer	1.68e-05	0.000144	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—FOXO1—muscle cancer	1.68e-05	0.000143	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IGF2—muscle cancer	1.68e-05	0.000143	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PTCH1—muscle cancer	1.67e-05	0.000143	CbGpPWpGaD
Ponatinib—LYN—Axon guidance—VEGFA—muscle cancer	1.67e-05	0.000143	CbGpPWpGaD
Ponatinib—ABL1—Axon guidance—VEGFA—muscle cancer	1.66e-05	0.000142	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—MDM2—muscle cancer	1.66e-05	0.000142	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—FH—muscle cancer	1.65e-05	0.000142	CbGpPWpGaD
Ponatinib—SRC—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	1.65e-05	0.000141	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—FOXO1—muscle cancer	1.64e-05	0.00014	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PTCH1—muscle cancer	1.64e-05	0.00014	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—MDM2—muscle cancer	1.62e-05	0.000139	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.62e-05	0.000139	CbGpPWpGaD
Ponatinib—KIT—Immune System—FOXO1—muscle cancer	1.61e-05	0.000138	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—FOXO1—muscle cancer	1.61e-05	0.000138	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—MDM2—muscle cancer	1.6e-05	0.000136	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—KIT—muscle cancer	1.59e-05	0.000136	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—MDM2—muscle cancer	1.58e-05	0.000135	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—MDM2—muscle cancer	1.57e-05	0.000135	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PTCH1—muscle cancer	1.56e-05	0.000133	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PTCH1—muscle cancer	1.55e-05	0.000133	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—FOXO1—muscle cancer	1.54e-05	0.000132	CbGpPWpGaD
Ponatinib—LCK—Disease—HMGA1—muscle cancer	1.54e-05	0.000132	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—FOXO1—muscle cancer	1.53e-05	0.000131	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—FOXO1—muscle cancer	1.53e-05	0.000131	CbGpPWpGaD
Ponatinib—FGFR2—Disease—FOXO1—muscle cancer	1.52e-05	0.00013	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—MDM2—muscle cancer	1.51e-05	0.00013	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—MDM2—muscle cancer	1.51e-05	0.000129	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—MED12—muscle cancer	1.51e-05	0.000129	CbGpPWpGaD
Ponatinib—SRC—Disease—ENO2—muscle cancer	1.5e-05	0.000128	CbGpPWpGaD
Ponatinib—LCK—Immune System—FOXO4—muscle cancer	1.49e-05	0.000128	CbGpPWpGaD
Ponatinib—KIT—Disease—FOXO1—muscle cancer	1.49e-05	0.000127	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IGF2—muscle cancer	1.46e-05	0.000125	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—KIT—muscle cancer	1.44e-05	0.000124	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.44e-05	0.000123	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—FH—muscle cancer	1.44e-05	0.000123	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—FOXO4—muscle cancer	1.44e-05	0.000123	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—MDM2—muscle cancer	1.43e-05	0.000123	CbGpPWpGaD
Ponatinib—FGFR1—Disease—FOXO1—muscle cancer	1.41e-05	0.000121	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—FOXO4—muscle cancer	1.41e-05	0.000121	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CNR1—muscle cancer	1.41e-05	0.000121	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—FOXO1—muscle cancer	1.41e-05	0.000121	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.4e-05	0.00012	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.39e-05	0.000119	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—MDM2—muscle cancer	1.39e-05	0.000119	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—KIT—muscle cancer	1.39e-05	0.000119	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CNR1—muscle cancer	1.39e-05	0.000119	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—MDM2—muscle cancer	1.38e-05	0.000118	CbGpPWpGaD
Ponatinib—LCK—Disease—FOXO4—muscle cancer	1.38e-05	0.000118	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ENO2—muscle cancer	1.37e-05	0.000117	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTCH1—muscle cancer	1.37e-05	0.000117	CbGpPWpGaD
Ponatinib—SRC—Disease—HMGA1—muscle cancer	1.36e-05	0.000116	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—FH—muscle cancer	1.36e-05	0.000116	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—VEGFA—muscle cancer	1.36e-05	0.000116	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—VEGFA—muscle cancer	1.35e-05	0.000115	CbGpPWpGaD
Ponatinib—LYN—Immune System—FOXO1—muscle cancer	1.35e-05	0.000115	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—FOXO1—muscle cancer	1.34e-05	0.000115	CbGpPWpGaD
Ponatinib—ABL1—Immune System—FOXO1—muscle cancer	1.34e-05	0.000115	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—FOXO4—muscle cancer	1.34e-05	0.000115	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—FOXO4—muscle cancer	1.34e-05	0.000114	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—MDM2—muscle cancer	1.33e-05	0.000114	CbGpPWpGaD
Ponatinib—SRC—Immune System—FOXO4—muscle cancer	1.32e-05	0.000113	CbGpPWpGaD
Ponatinib—FGFR3—Disease—MDM2—muscle cancer	1.32e-05	0.000113	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CNR1—muscle cancer	1.32e-05	0.000112	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CNR1—muscle cancer	1.31e-05	0.000112	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—KIT—muscle cancer	1.28e-05	0.000109	CbGpPWpGaD
Ponatinib—FGFR3—Disease—PTGS2—muscle cancer	1.28e-05	0.000109	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MDM2—muscle cancer	1.25e-05	0.000107	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—KIT—muscle cancer	1.25e-05	0.000107	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—KIT—muscle cancer	1.23e-05	0.000105	CbGpPWpGaD
Ponatinib—SRC—Disease—FOXO4—muscle cancer	1.22e-05	0.000104	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—VEGFA—muscle cancer	1.21e-05	0.000104	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—VEGFA—muscle cancer	1.19e-05	0.000102	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—VEGFA—muscle cancer	1.19e-05	0.000102	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—FOXO4—muscle cancer	1.18e-05	0.000101	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KIT—muscle cancer	1.18e-05	0.000101	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—VEGFA—muscle cancer	1.17e-05	0.0001	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KIT—muscle cancer	1.17e-05	9.98e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—VEGFA—muscle cancer	1.16e-05	9.96e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KIT—muscle cancer	1.16e-05	9.95e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CNR1—muscle cancer	1.16e-05	9.9e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KIT—muscle cancer	1.16e-05	9.88e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IGF2—muscle cancer	1.15e-05	9.87e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—MDM2—muscle cancer	1.14e-05	9.73e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IGF2—muscle cancer	1.13e-05	9.69e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTCH1—muscle cancer	1.12e-05	9.61e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—FOXO1—muscle cancer	1.1e-05	9.44e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.1e-05	9.37e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—MDM2—muscle cancer	1.09e-05	9.34e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—MED12—muscle cancer	1.08e-05	9.23e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KIT—muscle cancer	1.08e-05	9.21e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IGF2—muscle cancer	1.08e-05	9.2e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KIT—muscle cancer	1.07e-05	9.19e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IGF2—muscle cancer	1.07e-05	9.17e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—FOXO1—muscle cancer	1.06e-05	9.08e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—FOXO1—muscle cancer	1.04e-05	8.92e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—KIT—muscle cancer	1.03e-05	8.78e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KIT—muscle cancer	1.02e-05	8.76e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KIT—muscle cancer	1.02e-05	8.74e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TP53—muscle cancer	1.02e-05	8.72e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—FOXO1—muscle cancer	1.02e-05	8.72e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—MDM2—muscle cancer	1.01e-05	8.61e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTCH1—muscle cancer	9.95e-06	8.51e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—FOXO1—muscle cancer	9.9e-06	8.46e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—FOXO1—muscle cancer	9.87e-06	8.44e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—MDM2—muscle cancer	9.85e-06	8.43e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ENO2—muscle cancer	9.84e-06	8.42e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—FOXO1—muscle cancer	9.77e-06	8.36e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—MDM2—muscle cancer	9.68e-06	8.28e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—MDM2—muscle cancer	9.67e-06	8.27e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FOXO4—muscle cancer	9.66e-06	8.26e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—VEGFA—muscle cancer	9.59e-06	8.2e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—VEGFA—muscle cancer	9.51e-06	8.13e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CNR1—muscle cancer	9.48e-06	8.11e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IGF2—muscle cancer	9.46e-06	8.09e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MED12—muscle cancer	9.35e-06	8e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MDM2—muscle cancer	9.26e-06	7.92e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—MDM2—muscle cancer	9.18e-06	7.86e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—MDM2—muscle cancer	9.16e-06	7.84e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—MDM2—muscle cancer	9.1e-06	7.78e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—FOXO1—muscle cancer	9.02e-06	7.72e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—MDM2—muscle cancer	8.94e-06	7.64e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—FH—muscle cancer	8.88e-06	7.6e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TP53—muscle cancer	8.84e-06	7.56e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TP53—muscle cancer	8.8e-06	7.53e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PTGS2—muscle cancer	8.77e-06	7.5e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—FOXO1—muscle cancer	8.71e-06	7.45e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—VEGFA—muscle cancer	8.66e-06	7.4e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—PTGS2—muscle cancer	8.61e-06	7.37e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FOXO4—muscle cancer	8.55e-06	7.32e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ENO2—muscle cancer	8.52e-06	7.29e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—VEGFA—muscle cancer	8.49e-06	7.26e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MDM2—muscle cancer	8.48e-06	7.25e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MDM2—muscle cancer	8.46e-06	7.23e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KIT—muscle cancer	8.41e-06	7.19e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CNR1—muscle cancer	8.4e-06	7.18e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	8.28e-06	7.08e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PTGS2—muscle cancer	8.18e-06	6.99e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PTGS2—muscle cancer	8.15e-06	6.97e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MED12—muscle cancer	8.14e-06	6.97e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KIT—muscle cancer	8.09e-06	6.92e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—MDM2—muscle cancer	8.08e-06	6.91e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MDM2—muscle cancer	8.07e-06	6.9e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—MDM2—muscle cancer	8.04e-06	6.88e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KIT—muscle cancer	7.76e-06	6.64e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IGF2—muscle cancer	7.75e-06	6.63e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MED12—muscle cancer	7.67e-06	6.56e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KIT—muscle cancer	7.54e-06	6.45e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KIT—muscle cancer	7.52e-06	6.43e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KIT—muscle cancer	7.45e-06	6.37e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ENO2—muscle cancer	7.42e-06	6.35e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—muscle cancer	7.25e-06	6.2e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PTGS2—muscle cancer	7.24e-06	6.19e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—muscle cancer	7.19e-06	6.15e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FOXO1—muscle cancer	7.14e-06	6.1e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—VEGFA—muscle cancer	7.03e-06	6.02e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ENO2—muscle cancer	7e-06	5.98e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KIT—muscle cancer	6.87e-06	5.88e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF2—muscle cancer	6.86e-06	5.87e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.66e-06	5.7e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KIT—muscle cancer	6.63e-06	5.67e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MDM2—muscle cancer	6.62e-06	5.67e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—muscle cancer	6.42e-06	5.49e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MDM2—muscle cancer	6.37e-06	5.45e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FOXO1—muscle cancer	6.32e-06	5.4e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MDM2—muscle cancer	6.26e-06	5.35e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—VEGFA—muscle cancer	6.13e-06	5.24e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MDM2—muscle cancer	6.12e-06	5.23e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MDM2—muscle cancer	5.94e-06	5.08e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MDM2—muscle cancer	5.92e-06	5.07e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTGS2—muscle cancer	5.9e-06	5.04e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MDM2—muscle cancer	5.86e-06	5.02e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KIT—muscle cancer	5.44e-06	4.65e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MDM2—muscle cancer	5.41e-06	4.63e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—muscle cancer	5.32e-06	4.55e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MDM2—muscle cancer	5.22e-06	4.47e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—muscle cancer	5.22e-06	4.46e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MED12—muscle cancer	5.02e-06	4.29e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—muscle cancer	4.84e-06	4.14e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KIT—muscle cancer	4.81e-06	4.12e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—muscle cancer	4.78e-06	4.09e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—muscle cancer	4.75e-06	4.06e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—muscle cancer	4.63e-06	3.96e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO2—muscle cancer	4.57e-06	3.91e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—muscle cancer	4.51e-06	3.86e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—muscle cancer	4.5e-06	3.85e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MDM2—muscle cancer	4.28e-06	3.66e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—muscle cancer	3.97e-06	3.39e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MDM2—muscle cancer	3.79e-06	3.24e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—muscle cancer	3.66e-06	3.13e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—muscle cancer	3.59e-06	3.07e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—muscle cancer	3.43e-06	2.93e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—muscle cancer	3.41e-06	2.91e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—muscle cancer	3.4e-06	2.91e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—muscle cancer	3.25e-06	2.78e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—muscle cancer	3e-06	2.56e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—muscle cancer	2.97e-06	2.54e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—muscle cancer	2.88e-06	2.46e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—muscle cancer	2.59e-06	2.21e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—muscle cancer	2.46e-06	2.1e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—muscle cancer	2.44e-06	2.08e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—muscle cancer	2.18e-06	1.86e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—muscle cancer	1.59e-06	1.36e-05	CbGpPWpGaD
